, 1999, Vol. 397, 436–441.
10 D’arc M. et al. Origin of the HIV-1 group O epidemic in western lowland gorillas // PNAS, 2015, Vol. 112, No. 11, E1343–E1352.
11 Chen Z. et al. Genetic characterization of new West African simian immunodefciency virus SIVsm: geographic clustering of household-derived SIV strains with human immuno-defciency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop // Journal of Virology, June 1996, Vol. 70, No. 6, 3617–3627.
12 Kalish M. et al. Central African hunters exposed to Simian immunodefciency virus // Emerging Infectious Diseases, 2005 Dec., Vol. 11(12), 1928–1930.
13 Gilbert T. et al. The emergence of HIV/AIDS in the Americas and beyond // PNAS, 2007, Vol. 104, No. 47, 18566– 18570.
14 Пиневич А. В., Сироткин А. К., Гаврилова О. В., Потехин А. А. Вирусология: учебник. СПб.: Издательство Санкт-Петербургского университета, 2012. 432 с.
15 Ярилин А. А. Иммунология: учебник. М.: ГЭОТАР-Медиа, 2010. 752 с.
16 Атлас по медицинской микробиологии, вирусологии и иммунологии: Учебное пособие для студентов медицинских вузов / под ред. А. А. Воробьева, А. С. Быкова. М.: Медицинское информационное агентство, 2003. 236 с.
17 Doitsh G. et al. Cell death by pyroptosis drives CD4 T– cell depletion in HIV-1 infection // Nature, Jan. 2014, Vol. 505, 509–514.
18 The Durban Declaration // Nature, July 2000, Vol. 406, 15–16. Доступна по ссылке: http://www.nature.com/nature/journal/ v406/n6791/full/406015a0.html
19 De Clercq, E. The history of antiretrovirals: key discoveries over the past 25 years // Reviews in Medical Virology, Sep. 2009, Vol. 19, Issue 5, 287–299.
20 Volberding P. et al. Zidovudine in asymptomatic human immunodefciency virus infection. A controlled trial in persons with fewer than 50 °CD4-positive cells per cubic millimeter // New England Journal of Medicine, 1990, Vol. 322(14), 941–949.
21 Dournon E. et al. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex // Lancet, Dec. 1988, Vol. 332, No. 8623, 1297–1302.
22 Connor E. et al. Reduction of maternal-infant transmission of human immunodefciency virus type 1 with zidovu-dine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group // New England Journal of Medicine, Nov. 1994, 3; Vol. 331(18), 1173–1180.
23 Larder B, Kemp A. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT) // Science, Dec. 1989: Vol. 246, No. 4934, 1155–1158.
24 Hammer S. et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodefcien-cy virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team //